Human EGFR Monoclonal Antibody (YR0122)

Basic Information

Clone	Matuzumab Biosimilar
Molecular Weight	150 kDa
Endotoxin	<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay
Sterility	0.2 μm filtration
Aggregation	<5% Determined by SECP
Purity	>95% Determined by SDS-PAGE

Product Information

Production	Purified from cell culture supernatant in an animal-free facility
Purification	Protein A or G purification
Storage	2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)

Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival.Matuzumab binds the epidermal growth factor receptor (EGFR) with high affinity, competitively blocking natural ligand binding and blocking receptor-mediated downstream signalling, resulting in impaired tumor cell proliferation. Matuzumab (EMD-72000) is a humanized IgG1 MAb that not only binds with high specificity and affinity to EGFR, but also modulates antibody-dependent cellular cytotoxicity (ADCC).

Immunogen Information

Isotype	Human IgG1 kappa
Immunogen	Human EGFR
RecommendedIsotype Control(s)	In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody
Recommended Dilution Buffer	1×PBS pH 7.0

* For research use only. Not for therapeutic or diagnostic purposes.